Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT05930899
Recruiting Observational

Translational-Omics in Aortic Stenosis (TOmAS) Biobank

NCT05930899 · tracked via the Priya Life Science Canada tracker
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Observational
Started
2017-10-12
Last updated
2024-11-20

Condition(s) studied

Cardiovascular DiseasesAortic Valve Stenosis

Investigational drug(s) / intervention(s)

Genetics

Genetics: TOmAS is a biobank and all patients will be genotyped

Study summary

The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection. * Undergoing cardiac surgery for non-aortic valve pathology Exclusion Criteria: * Individuals with Congenital heart disease will be excluded

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Montreal General Hospital Montreal Quebec Recruiting
Royal Victoria Hospital Montreal Quebec Recruiting

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Evaluating a Wireless NIRS Device in the Neonatal Intensive Care Unit Recruiting
Evaluating the Feasibility of elleFA App Implementation Recruiting
Helping Couples Communicate Better: Does This Help Persons With Type 2 Diabetes Respond Better to a Step Count Prescription? Recruiting
Detection of Respiratory Events Using Acoustic Monitoring in Extremely Preterm Infants Recruiting
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance Starting soon

Other trials for the same condition

Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis. Recruiting
Effectiveness of a Customized Digital Platform to Increase Coordination of Care and Uptake of Evidence-based Practices Starting soon
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR Recruiting
Higher vs. Lower Dose Heparin for PCI Recruiting
iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05930899 on ClinicalTrials.gov ↗ ← All trials in Canada